Management of Stroke in Patients with Left Ventricular Assist Devices

J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105166. doi: 10.1016/j.jstrokecerebrovasdis.2020.105166. Epub 2020 Aug 12.

Abstract

Introduction: The number of patients with left ventricular assist devices (LVAD) is rapidly growing in industrialized countries. While cerebrovascular events comprise a significant complication, data on stroke etiology, clinical management and functional outcome are scarce.

Methods: Consecutive LVAD patients with ischemic or hemorrhagic stroke receiving treatment at an university stroke center between 2010 and 2018 were included into an institutional registry. Clinical characteristics, causes, management and functional outcome of stroke occurring within this cohort are reported. Acceptable functional outcome was defined as mRS 0-3.

Results: N = 30 acute strokes occurred in 20 patients (77% ischemic, 23% hemorrhagic, mean age 57 ± 13 years, 10% female, 8 patients (40%) had more than one event). 87% of all events happened with non-pulsatile devices, on average 9 (IQR 3-22) months after the implantation. All patients used oral anticoagulation with a Vitamin-K antagonist in combination with anti-platelets. The international normalized ratio (INR)-values were outside the therapeutic range in 39% of ischemic strokes and in 57% of hemorrhagic strokes. Ischemic strokes were predominantly of cardioembolic origin (92%) and of mild to moderate clinical severity (median NIHSS 6 (IQR 4-10). None qualified to receive intravenous thrombolysis or intra-arterial endovascular therapy. 61% of IS-patients showed an acceptable functional outcome after three months. 4/7 patients with hemorrhagic stroke received immediate reversal of anticoagulation without any thrombotic complications.

Conclusion: The majority of LVAD patients with ischemic stroke had an acceptable functional outcome after three months. Future clinical research is warranted to improve therapeutic strategies for acute care and stroke prevention.

Keywords: Functional outcome; Intracerebral hemorrhage; Ischemic stroke; Left ventricular assist devices.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Brain Ischemia / diagnosis
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / physiopathology
  • Disability Evaluation
  • Female
  • Heart Diseases / diagnosis
  • Heart Diseases / physiopathology
  • Heart Diseases / therapy*
  • Heart-Assist Devices*
  • Humans
  • Intracranial Hemorrhages / diagnosis
  • Intracranial Hemorrhages / drug therapy*
  • Intracranial Hemorrhages / physiopathology
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Recovery of Function
  • Registries
  • Stroke / diagnosis
  • Stroke / drug therapy*
  • Stroke / physiopathology
  • Time Factors
  • Treatment Outcome
  • Ventricular Function, Left*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors